Intech Investment Management LLC Grows Stock Holdings in TG Therapeutics, Inc. $TGTX

Key Points

• Intech Investment Management LLC increased its shares in TG Therapeutics, Inc. by 20.5%, bringing its total to 86,527 shares, valued at approximately $3.4 million.
• Goldman Sachs upgraded TG Therapeutics to a "hold" rating with a price objective of $37.00, while the stock currently has an average consensus target price of $46.25.
• Insider activity was noted as Director Sagar Lonial sold over 20,000 shares, decreasing his position by 18.15% following the transaction.

Intech Investment Management LLC lifted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 20.5% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 86,527 shares of the biopharmaceutical company's stock after purchasing an additional 14,694 shares during the period. Intech Investment Management LLC owned about 0.05% of TG Therapeutics worth $3,412,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of TGTX. NBC Securities Inc. lifted its position in TG Therapeutics by 82,300.0% in the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 823 shares during the last quarter. Golden State Wealth Management LLC increased its stake in shares of TG Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 433 shares during the period. SVB Wealth LLC purchased a new position in shares of TG Therapeutics during the first quarter valued at approximately $37,000. Vermillion Wealth Management Inc. bought a new position in shares of TG Therapeutics during the fourth quarter valued at approximately $30,000. Finally, USA Financial Formulas purchased a new stake in TG Therapeutics in the first quarter worth $57,000. Institutional investors own 58.58% of the company's stock.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group raised TG Therapeutics to a "hold" rating and set a $37.00 price objective on the stock in a research report on Thursday, July 10th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $46.25.

Insider Activity at TG Therapeutics

In other news, Director Sagar Lonial sold 20,852 shares of the company's stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the completion of the sale, the director owned 94,061 shares of the company's stock, valued at $3,032,526.64. This represents a 18.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.64% of the stock is owned by insiders.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $32.16 on Friday. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. The company has a 50 day moving average price of $32.38 and a 200-day moving average price of $35.67. TG Therapeutics, Inc. has a 52 week low of $21.16 and a 52 week high of $46.48. The firm has a market capitalization of $5.10 billion, a PE ratio of 86.92 and a beta of 1.88.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.15). TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The company had revenue of $141.15 million during the quarter, compared to analysts' expectations of $147.76 million. During the same quarter in the prior year, the business posted $0.04 EPS. The company's revenue for the quarter was up 92.1% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.